<DOC>
	<DOCNO>NCT00146172</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability well find maximum tolerate dose HKI-272 . In addition , study examine effect study drug tumor , body use eliminate HKI-272 .</brief_summary>
	<brief_title>Study Evaluating HKI-272 Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Her2/neu Her1/EGFR positive cancer ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 Measurable disease define RECIST ( Response Evaluation Criteria Solid Tumors ) Prior treatment anthracyclines cumulative dose doxorubicin equivalent great 300 mg/m2 Patients significant cardiac risk factor Active central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumors</keyword>
</DOC>